Mfn2 (Mitofusin 2) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
MFN2 (Mitofusin 2) is a nuclear-encoded mitochondrial outer membrane protein that plays a critical role in mitochondrial fusion, a fundamental process in mitochondrial dynamics. It is encoded by the MFN2 gene located on chromosome 1p36.22. MFN2 is essential for maintaining mitochondrial morphology, distribution, and function, and its dysfunction has been implicated in various neurodegenerative diseases, including Charcot-Marie-Tooth disease type 2A (CMT2A), Parkinson's disease, and Alzheimer's disease[1][2].
| Attribute | Value |
|---|---|
| Gene Symbol | MFN2 |
| Full Name | Mitofusin 2 |
| Chromosomal Location | 1p36.22 |
| NCBI Gene ID | 9927 |
| OMIM ID | 608507 |
| Ensembl ID | ENSG00000116688 |
| UniProt ID | O95140 |
| Associated Diseases | Charcot-Marie-Tooth Disease Type 2A (CMT2A), Hereditary Motor and Sensory Neuropathy VI (HMSN6) |
MFN2 is one of three mitofusin proteins (MFN1, MFN2, and MFN3) in mammals that mediate mitochondrial outer membrane fusion. MFN2 functions as a GTPase, undergoing conformational changes that bring opposing mitochondrial outer membranes together for fusion[1:1].
Key functions include:
CMT2A is the most common form of autosomal dominant axonal CMT, caused by MFN2 mutations. Over 40 pathogenic variants have been identified, predominantly affecting the GTPase domain and heptad repeat regions[3].
Clinical features:
Emerging evidence links MFN2 dysfunction to PD pathogenesis:
MFN2 is widely expressed in human tissues, with high expression in:
In the brain, MFN2 is particularly important in:
| Approach | Status | Description |
|---|---|---|
| Gene Therapy | Preclinical | AAV-MFN2 delivery for CMT2A |
| Small Molecule Activators | Research | Compounds promoting MFN2 GTPase activity |
| Mitochondrial Dynamics Modulators | Research | Balancing fusion/fission for neuroprotection |
| Antioxidants | Clinical | Mitigating oxidative stress from mitochondrial dysfunction |
The study of Mfn2 (Mitofusin 2) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Chen Y, et al. (2012). Mitofusin 2 deficiency leads to oxidative stress and metabolic syndrome. Cell Research. 22(8): 1245-1246. PMID:22751438 ↩︎ ↩︎ ↩︎
Gautam M, et al. (2019). Mfn2 deficiency is associated with impaired mitophagy and accelerated aging in Parkinson's disease. Autophagy. 15(5): 895-897. PMID:31155716 ↩︎ ↩︎ ↩︎ ↩︎
Zuchner S, et al. (2004). Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nature Genetics. 36(5): 449-451. PMID:15155950 ↩︎ ↩︎